文献速递头颈外科

西妥昔单抗对比卡铂为基础的放化疗用于头颈癌患者

Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2022-01-01

该队列研究纳入2006年1月至2020年12月诊断的8290例美国退伍军人非转移性头颈鳞癌患者,比较西妥昔单抗与卡铂为基础放化疗的总生存。倾向评分加权后,卡铂组总生存优于西妥昔单抗组(cause-specific HR 0.85,95%CI 0.78-0.93,P=0.001),口咽亚组差异明显。

要点

  • 卡铂为基础放化疗较西妥昔单抗与总生存改善相关(HR 0.85,95%CI 0.78-0.93,P=0.001)。
  • 中位总生存:顺铂组74.4个月,卡铂组43.4个月,西妥昔单抗组31.1个月。
  • 口咽亚组中卡铂与西妥昔单抗的总生存差异明显。

核心结论

  • 在倾向评分匹配后,卡铂为基础的系统治疗较西妥昔单抗与总生存改善15%相关,提示卡铂可能是首选的放射增敏剂,尤其在口咽癌中。

研究设计与样本

  • 美国退伍军人队列研究,纳入2006年1月至2020年12月诊断并接受系统治疗和放疗的8290例非转移性头颈鳞癌患者,数据截止2022年3月1日,分析于2022年4月至5月进行。

主要发现

  • 8290例患者中,顺铂组5566例(67%),卡铂组1231例(15%),西妥昔单抗组1493例(18%)。
  • 中位总生存:顺铂放疗组74.4个月(IQR 22.3-162.2),卡铂放疗组43.4个月(IQR 15.3-123.8),西妥昔单抗放疗组31.1个月(IQR 12.4-87.8)。
  • 与顺铂组相比,卡铂组和西妥昔单抗组患者年龄更大、体力状态评分更差、合并症负担更高。
  • 倾向评分及逆概率加权后,卡铂较西妥昔单抗与总生存改善相关(cause-specific HR 0.85,95%CI 0.78-0.93,P=0.001)。
  • 该差异在口咽亚组中明显。

临床怎么用

  • 作者认为卡铂可能是首选的放射增敏剂,尤其在口咽癌中。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Cetuximab-based and carboplatin-based chemoradiotherapy (CRT) are often used for patients with locally advanced head and neck cancer who are ineligible for cisplatin. There are no prospective head-to-head data comparing cetuximab-based and carboplatin-based regimens for radiosensitization. OBJECTIVE: To compare survival with cetuximab-based and carboplatin-based CRT in locally advanced head and neck squamous cell carcinoma (HNSCC). DESIGN, SETTING, AND PARTICIPANTS: This cohort study included US veterans who received a diagnosis of HNSCC between January 2006 and December 2020 and were treated with systemic therapy and radiation. Data cutoff was March 1, 2022 and data analysis was conducted from April-May 2022. EXPOSURES: Cisplatin, cetuximab, or carboplatin-based systemic therapy as captured in VA medication data and cancer registry. MAIN OUTCOMES AND MEASURES: Overall survival by systemic therapy was estimated using Kaplan-Meier methods. We used propensity score and inverse probability weighting to achieve covariate balance between cetuximab-treated and carboplatin-treated patients and used Cox regression to estimate cause-specific hazard ratios of death associated with carboplatin vs cetuximab. We also performed subgroup analyses of patients with oropharynx vs nonoropharynx primary sites. RESULTS: A total of 8290 patients (median [IQR] age, 63 [58-68] years; 8201 men [98.9%]; 1225 [15.8%] Black or African American and 6424 [82.6%] White individuals) with nonmetastatic HNSCC were treated with CRT with cisplatin (5566 [67%]), carboplatin (1231 [15%]), or cetuximab (1493 [18%]). Compared with cisplatin-treated patients, patients treated with carboplatin and cetuximab were older with worse performance status scores and higher comorbidity burden. Median (IQR) overall survival was 74.4 (22.3-162.2) months in patients treated with cisplatin radiotherapy (RT), 43.4 (15.3-123.8) months in patients treated with carboplatin RT, and 31.1 (12.4-87.8) months in patients treated with cetuximab RT. After propensity score and inverse probability weighting, carboplatin was associated with improved overall survival compared with cetuximab (cause-specific hazard ratio, 0.85; 95% CI, 0.78-0.93; P = .001). This difference was prominent in the oropharynx subgroup. CONCLUSIONS AND RELEVANCE: In this cohort study of a US veteran population with HNSCC undergoing treatment with CRT, almost a third of patients were ineligible to receive treatment with cisplatin and received cetuximab-based or carboplatin-based radiosensitization. After propensity score matching, carboplatin-based systemic therapy was associated with 15% improvement in overall survival compared with cetuximab, suggesting that carboplatin may be the preferred radiosensitizer, particularly in oropharynx cancers.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Sun L, Candelieri-Surette D, Anglin-Foote T, et al. Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2022. PMID: 36136306. doi:10.1001/jamaoto.2022.2791

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。